The landmark collaboration will accelerate research and development initiatives for respiratory diseases, rare diseases, diseases of prematurity, and other speciality care indications. One of the first research areas will be preterm birth-associated early-onset respiratory disease.
Chiesi Group, a research-oriented international biopharmaceutical group, proudly announces the signing of a memorandum of understanding with Karolinska Institutet, a medical university. The agreement solidifies a commitment between the two organisations to collaborate on joint efforts to advance therapeutic solutions for urgent health challenges.
The landmark collaboration between Chiesi and Karolinska Institutet (KI), will accelerate research and development initiatives for respiratory diseases, rare diseases, diseases of prematurity, and other speciality care indications.
Chiesi Group and KI will exchange ideas, expertise, and resources to accelerate the translation of scientific discoveries into tangible healthcare solutions. Their collaboration is underpinned by a shared commitment to advancing medical science and improving patient care through joint research, development, and innovation efforts.
Fabrizio Conicella, Head of Chiesi’s Centre for Open Innovation and Competence, said: “We believe that this partnership with such a world-renowned academic centre of excellence will provide significant opportunities to not only accelerate our pipeline but to explore and establish novel innovative ways of working between academia and industry”.
Mark Parry-Billings, Head of Drug Development at Chiesi and Site Head of Chiesi’s R&D operations based in the Karolinska Science Park said, “We are delighted to advance our work with KI through this collaborative agreement, which will leverage past successes and form a platform for a close and dynamic research and development partnership, in a series of focused scientific disciplines, including for example in the field of translational medicine”.
Åsa Wheelock, Board member of the Chiesi-KI alliance and Head of the Respiratory Medicine Unit, Department of Medicine Solna, at KI, said, “We are thrilled to embark on this strategic collaboration with Chiesi Group, a partnership that embodies our shared commitment to advancing scientific research and improving patient care. KI and Chiesi have a long and successful track record of collaborations in the field of respiratory disease and neonatology. This alliance provides an enhanced platform to expand our collaborations beyond our ongoing joint efforts on the sub-grouping of patients in the asthma-COPD spectrum. As such, this collaboration underscores Karolinska Institutet’s dedication to translating cutting-edge research into tangible solutions that address the needs of patients worldwide”.
Through this partnership, Chiesi Group and KI are poised to drive innovation, accelerate scientific discovery, and ultimately improve patient outcomes in areas of high unmet need.
